Double-blind placebo-controlled study of velnacrine in Alzheimer's disease

Life Sciences

Volumn 58, Issue 21, 1996, Pages 1823-1832

  Zemlan, Frank P ^a   Keys, Michael ^a   Richter, Ralph W ^b   Strub, Richard L ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Alzheimer's Center   (United States)

^c OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Alzheimer's disease; cholinesterase inhibitors; cholinomimetic; velnacrine

Indexed keywords

AMINOTRANSFERASE; CHOLINESTERASE INHIBITOR; LIVER ENZYME; PLACEBO; VELNACRINE;

ABDOMINAL PAIN; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; TREATMENT OUTCOME; VOMITING;

EID: 0029924782     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(96)00166-X     Document Type: Article

References (23)

1. D.A. EVANS, H.H. FUNKENSTEIN, M.S. ALBERT, et al., J. Am. Med. Assoc. 262 2551-2556 (1989).
2. J.S. SMITH, L.G. KILOH. Lancet 1 824-827 (1981).
3. M.-M. MESULAM. Neuroscience 17 275-276 (1986).
4. R.D. TERRY, A. PECK, R. DeTERESA et al,. Ann. Neural. 10 184-192 (1981).
5. P.J. WHITEHOUSE, D.L. PRICE, R.G. STRUBE et al., Science 211 1237-1239 (1982).
6. B.E. TOMLINSON, D. IRVING, G. BLESSED. J. Neurol. Sci. 49 419-428 (1981).
7. D.M. MANN, P.O. YATES, B. MARCYNIUK. J. Neurol. Neurosurg. Psychiatry 47 201-203 (1984).
8. C.B. SAPER, D.E.C. GERMAN, C.L. WHITE. Neurology 25 1089-1095 (1985).
9. C. GEULA, M.-M. MESULAM. Neuroscience 22 469-481 (1989).
10. G.M. SHUTSKE, F.A. PIERRAT, K.J. KAPPLES et al., J. Med. Chem. 22 1805-1813 (1989).
11. Y. TANAKA, M. SUKURI, S. HAYASHI. Neurosci. Lett. 98 179-183 (1989).
12. S.K. PURI, R. HSU, I. HO. J. Clin. Pharmacol. 29 278-284 (1989).
13. S.K. PURI, I. HO, R. HSU. J. Clin. Pharmacol. 30 948-955 (1990).
14. M.F. MURPHY, S.T. HARDIMAN, R.J. NASH et al., Ann. N.Y. Acad. Sci. 640 253-262 (1991).
15. G. McKHANN, D. DRACHMAN, M. FOLSTEIN et al., Neurology 24 939-944 (1984).
16. M. FOLSTEIN, S. FOLSTEIN, R.R. McHUGH. J. Psychiatry Res. 12 189-198 (1975).
17. W.G. ROSEN, R.D. TERRY, P.A. FULD. Ann. Neurol. 7 486-488 (1980).
18. W.G. ROSEN, R.C. MOHS, K.L. DAVIS. Am. J. Psychiat. 141 1356-1364 (1984).
19. W. GUY ECDEU Assessment Manual for Psychopharmacology, W. Guy (Ed), 218-222, National Institute of Mental Health, Rockville, MD (1976).
20. SAS Institute Inc. SAS User's Guide: Statistics, Version 5 Edition. 956 pp. Cary, NC: SAS Institute Inc., 1985.
21. K.L. DAVIS, L.J. THAL, E.R. GAMZU, et al. New Engl. J. Med. 327 1253-1259 (1992).
22. M. FARLOW, S.I. GRACON, L.A. HERSHEY et al., J. Am. Med. Assoc. 268 2523-2529 (1992).
23. F.J. EHLERT, W.R. ROESKE, H.I. YAMAMURA, Life Sciences 55 2135-2145 (1994).